It is about measuring our progress as a business based on core components that will sustain us on our path to be an integrated, immunology company. Our mission sits at the intersection of critical patient need and breakthrough science.
We are committed to deepening ESG integration into our core strategy, fostering a sustainable business that not only delivers value today but shapes a better tomorrow for patients, employees, our research collaborators, other stakeholders and the global community.
In 2024, we upheld our commitment to transparency and accountability as required by the European Union’s Non-Financial Reporting Directive (the NFRD), as implemented into Dutch legislation. In addition, the European Union’s Corporate Sustainability Reporting Directive (the CSRD) entered into force in January 2023. Being a company governed under Dutch law, the Dutch domestic law implementing the CSRD will apply to us. During 2024, draft legislation was proposed in the Netherlands to implement the CSRD, but was not yet adopted at the time of publication of the Annual Report 2024. In anticipation of implementation of the CSRD into Dutch domestic law with expected applicability in respect of annual reports starting financial year 2024, companies in scope of CSRD have been urged by the financial markets supervisory authority in the Netherlands to prepare and be ready for CSRD compliant reporting for their annual report 2024. In line with market practice in relation to annual reports for 2024 in the Netherlands, we have prepared our sustainability statement based on the general principles of the CSRD for the first time and integrated such sustainability statement into our Annual Report 2024. This sustainability statement is prepared in accordance with the European Sustainability Reporting Standards (ESRS), reflecting our dedication to comprehensive and accurate sustainability reporting. Additionally, we reference the Sustainability Accounting Standards Board (SASB) standards.